Hangzhou Highlightll Pharmaceutical Co., Ltd

Quick facts

Phase 3 pipeline

• TLL-018 · Diabetes
  TLL-018 is a small molecule that targets the SGLT2 receptor.
• TLL-018 tablets
  TLL-018 tablets' mechanism of action is not publicly available.

Phase 2 pipeline

• TLL018 tablets

Phase 1 pipeline

• TLL-018 immediate-release tablet

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Hangzhou Highlightll Pharmaceutical Co., Ltd portfolio CI brief
• Hangzhou Highlightll Pharmaceutical Co., Ltd pipeline updates RSS